8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2023

ALIMERA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34703		20-0028718
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)
6310 Town Square, Suite 400 Alpharetta, Georgia		30005
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address, if changed since last report.)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	ALIM	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

‎

‎

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b), (c)

On October 3, 2023, Alimera Sciences, Inc. (“Alimera” or the “Company”) announced its Board of Directors (the “Board”) appointed Jason Werner, 45, as the Company’s chief operating officer (the “COO Appointment”), effective October 2, 2023 (the “Effective Date”). Mr. Werner served as the Chief Executive Officer of SightStream Biotherapeutics Inc., a biotechnology company focused on developing regenerative medicines in ophthalmics from May 2021 until September 2023. Mr. Werner previously served as Co-Founder and Chief Operating Officer of Eyevance Pharmaceuticals Inc., a developer of topical ophthalmic products, from September 2017 through its acquisition by Santen Pharmaceutical Co., Ltd. in September 2020. Prior to that, Mr. Werner held various positions in Commercial Development and Global Strategy at Sun Pharmaceutical Industries Ltd. and Inspire Pharmaceuticals, Inc., as well as front line sales for Pfizer Inc. Mr. Werner received his B.S. in business administration from the University of New Hampshire.

Mr. Werner joined the Board as a Class II director in May 2023 as a designee of Velan Capital Investment Management LP. In connection with and prior to the COO Appointment, Mr. Werner resigned from the Company’s Board and all committees thereof. This resignation was not the result of any dispute or disagreement with Alimera or the Board on any matter relating to Alimera’s operations, policies, or practices. In connection with Mr. Werner’s resignation, pursuant to the Company’s bylaws and certificate of incorporation, the Board decreased the number of directors from eight to seven.

In connection with the COO Appointment, the title of Dr. Philip Ashman, the Company’s prior chief operating officer, was changed to President of International Operations.

Werner Employment Agreement

In connection with the COO Appointment, Mr. Werner and the Company entered into an employment agreement (the “Employment Agreement”) effective as of October 2, 2023. Pursuant to the terms of the Employment Agreement, Mr. Werner will receive an annual base salary of $450,000 (the “Base Salary”), a sign-on bonus of $50,000 and will also be eligible for a potential annual bonus of 40% of his then-current Base Salary (prorated for 2023 based on the Effective Date), subject to adjustment by the Board from time to time but not below 40% of his then-current Base Salary.

The Employment Agreement provides that Mr. Werner’s employment with the Company is “at will.” Mr. Werner is entitled to receive all other benefits generally available to the Company’s executive officers. The Employment Agreement also provides certain severance and change in control-related benefits, including cash severance and vesting acceleration upon the occurrence of certain defined events, as described below.

Severance and Change in Control Benefits

Acceleration Provisions for Unvested Options and Shares of Restricted Stock in the Event of a Change in Control

The Employment Agreement includes acceleration provisions for unvested options in the event Mr. Werner’s employment with the Company is terminated by the Company without cause or if Mr. Werner terminates his employment for good reason. Under these provisions, Mr. Werner will receive 12 months of additional vesting for any stock options that are outstanding and unvested as of the date of such transaction. In addition, Mr. Werner’s unvested stock options and unvested equity awards subject to time-based vesting will vest in full if (a) the Company is subject to a change in control and (b) within 3 months prior to a change in control, on a change in control, or 12 months after the change in control, his employment with the Company is terminated by the Company (or its successor) without cause or he terminates his employment for good reason. Additionally, Mr. Werner’s unvested restricted stock units subject to performance-based vesting (the “Performance RSUs”) will vest in full for the measurement year in which a change in control occurs (i) if certain performance-based vesting conditions are met

and (ii) if (a) the Company is subject to a change in control and (b) within 3 months prior to a change in control, on a change in control, or 12 months after the change in control, his employment with the Company is terminated by the Company (or its successor) without cause or he terminates his employment for good reason.

Further, if the Company is a party to a merger or consolidation, Mr. Werner’s unvested stock options and outstanding equity awards will vest in full unless the agreement evidencing the merger or consolidation provides for one or more of the following: (a) the continuation of his stock options and equity awards by the Company if the Company is the surviving corporation; (b) the assumption of his stock options and equity awards by the surviving corporation or its parent; (c) the substitution by the surviving corporation or its parent of new stock options and equity awards for his existing stock options and equity awards; (d) full exercisability of outstanding stock options and full vesting of the equity awards, followed by the cancellation of such stock options and equity awards in the transaction; or (e) the cancellation of Mr. Werner’s outstanding stock options and unvested equity awards and a payment to Mr. Werner equal to the excess of (i) the fair market value of the stock subject to such stock options and of the equity awards (whether or not such stock options and equity awards are then exercisable or vested, as applicable) as of the closing date of such merger or consolidation over (ii) the exercise price (for stock options).

Termination without Cause/Resignation for Good Reason Not in Connection with a Change in Control

In addition, the Employment Agreement provides that if the Company terminates Mr. Werner’s employment without cause or if he resigns for good reason, either more than three months prior to a change in control or more than 18 months after a change in control, subject to the conditions in the Employment Agreement, Mr. Werner will be entitled to:

his earned but unpaid base salary plus 100% of the sum of (i) his total annual base salary at the rate in effect at the time of termination plus (ii) his target annual bonus for the then current year paid in 12 monthly installments;

a cash payment equal to his bonus, determined based on the actual performance of the Company for the full fiscal year in which his employment terminates, that he would have earned for the year in which his employment terminates had he remained employed for the entire year, prorated based on the ratio of the number of days during such year he was employed to 365 (the “Earned Bonus”); and

payment of the premiums for medical insurance coverage for Mr. Werner and his dependents under COBRA for one year following the date of termination or, if earlier, until he is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer.

Termination without Cause/Resignation for Good Reason in Connection with a Change in Control

The Employment Agreement provides that if the Company terminates Mr. Werner’s employment without cause or if he resigns for good reason, either within three months prior to a change in control or within 18 months after a change in control, subject to the conditions in the Employment Agreement, Mr. Werner will be entitled to:

the sum of (a) 150% of his total annual base salary at the rate in effect at the time of termination plus (b) 100% of his target annual bonus for the then current year, which will be paid in 18 equal monthly installments;

a cash payment equal to his Earned Bonus;

payment of the premiums for medical insurance coverage for Mr. Werner and his dependents under COBRA for 18 months or until he is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer.

Benefits upon Death or Disability

Death

The Employment Agreement provides certain benefits if Mr. Werner’s employment is terminated on account of his death. In that event, the Company is obligated to pay:

(a) his base salary through the end of the month in which his death occurred,

(b) a cash payment equal to his Earned Bonus for the year in which his death occurred,

(c) any benefits he is entitled to under the terms of any applicable disability plans or other employee benefit plan, and

(d) the premiums for medical insurance coverage for his dependents under COBRA for one year after the date of death or, if earlier, until his dependents are eligible to be covered under another substantially equivalent medical insurance plan.

In addition, all of Mr. Werner’s remaining unvested equity awards will vest upon his death.

Disability

The Employment Agreement provides certain benefits if Mr. Werner’s employment is terminated on account of his disability. In that event, the Company is obligated to pay:

(a) his base salary through the end of the month in which the termination occurred,

(b) a cash payment equal to his Earned Bonus for the year in which the termination occurred,

(c) any benefits he is entitled to under the terms of any applicable disability plans or other employee benefit plan, and

(d) the premiums for medical insurance coverage for him and his dependents under COBRA for 18 months after the date of termination or, if earlier, until he is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer.

In addition, all of Mr. Werner’s remaining unvested equity awards will vest upon his disability.

A copy of the Employment Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The above description of the Employment Agreement contained herein is qualified in its entirety by the full text of such exhibit.

Werner Equity Awards

In connection with the COO Appointment, Mr. Werner received initial grants under the Company’s 2023 Equity Incentive Plan of (a) options to purchase 225,000 shares of the Company’s common stock, (b) 225,000 restricted stock units for shares of common stock subject to time-based vesting and (c) 225,000 Performance RSUs. The exercise price for the option was $2.99, the closing price of the Company’s common stock on the Nasdaq Global Market on October 2, 2023. 25% of the shares subject to the option will vest after 12 months of Mr. Werner’s continuous service, and the balance will vest in equal monthly installments over the next 36 months of continuous service. 25% of the restricted stock units subject to time-based vesting will vest after one year of Mr. Werner’s continuous service, and the balance will vest in equal yearly installments over the next three years of continuous service. Vesting of the Performance RSUs will be conditioned on the satisfaction of certain performance metrics related to the revenue target or stock price target. In the event that the restricted stock units for shares of common stock subject to time-based vesting and the Performance RSUs are accelerated as a result of Mr. Werner’s termination in connection with a change in control prior to August 1, 2024, then the vested restricted stock units for shares of common stock subject to time-based vesting and the vested Performance RSUs will be settled in cash.

Werner Indemnification Agreement

Mr. Werner has previously entered into the Company’s standard form of indemnification agreement.

No Other Arrangements or Understandings

There are no arrangements or understandings between Mr. Werner and any other persons pursuant to which he was appointed as chief operating officer of the Company. There are no family relationships between Mr. Werner and any of the Company’s directors or other executive officers, and Mr. Werner is not a party to any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On October 3, 2023, the Company issued a press release announcing the changes in its executive leadership. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01 is being “furnished” and not “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically identified as being incorporated therein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
10.1	Employment Agreement dated as of October 2, 2023 between Alimera Sciences, Inc. and Jason Werner
99.1	Press Release of Alimera Sciences, Inc. dated October 3, 2023
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

‎

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALIMERA SCIENCES, INC.
Dated: October 3, 2023	By:	/s/ Russell L. Skibsted
	Name:	Russell L. Skibsted
	Title:	Chief Financial Officer

EX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT WITH

ALIMERA SCIENCES, INC.

This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Jason Werner (“Executive”), as of October 2,  2023.

RECITALS:

WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and throughout the world;

WHEREAS, Company and Executive desire that Executive provide the Company employment services upon the terms and conditions set forth below;

WHEREAS,  as of the date hereof, Executive is a member of the Board; and

WHEREAS, the Company desires now to retain Executive as its Chief Operating Officereffective as of October 2, 2023 (the “Effective Date”), pursuant to the terms of this Agreement and to implement a competitive compensation and benefit package for Executive commensurate with his role.

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the parties, intending to be legally bound, agree as follows:

AGREEMENT:

SECTION 1 EFFECTIVE DATE; RESIGNATION FROM BOARD

Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as Chief Operating Officer, and Executive agrees to such employment by the Company as of the Effective Date.  

In connection therewith, as of the Effective Date, Executive hereby resigns as a member of the Board.

SECTION 2 DEFINITIONS

“2023 Plan” means the Alimera Sciences, Inc. 2023 Equity Incentive Plan, as amended and/or restated from time to time.

“Board” means the Board of Directors of the Company.

“Cause” means:

(1)Executive’s gross negligence or willful misconduct with respect to the business and affairs of the Company, including violation of any material policy or rule of the Company that is not cured within 30 days after written notice thereof is given to Executive by the Company;

(2)Executive’s conviction of, or entering a guilty plea or plea of no contest with respect to, a felony or to, a crime involving moral turpitude, deceit, dishonesty or fraud that is likely to inflict or has caused harm to the Company or any affiliate of the Company;  

(3)Executive engaging in any material breach of the terms of this Agreement or any agreement between Executive and the Company or failing to fulfill Executive’sduties and responsibilities under this Agreement or assigned or delegated to Executive and such breach or failure, as the case may be, is not cured, or is not capable of being cured, within 30 days after written notice thereof is given to Executive by the Company;

(4)Executive engaging in any intentional act of dishonesty, deceit, fraud, moral turpitude, misconduct, breach of trust or acts intentionally against the financial or business interests of the Company by Executive, or Executive’s use or possession of illegal drugs in the workplace; or

(5) Executive’s failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested Executive’s cooperation.

For purposes of this definition of Cause, no act, or failure to act, will be deemed “willful” or “intentional” if done or omitted to be done by Executive in good faith with a reasonable belief that Executive’s act, or failure to act, was in the best interest of the Company.

“Change in Control” means (i) the consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of (A) the continuing or surviving entity and (B) any direct or indirect parent corporation of such continuing or surviving entity or (ii) the sale, transfer or other disposition of all or substantially all of the Company’s assets. A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur unless such transaction also qualifies as a “change in control event” as described in Treas. Reg. § 1.409A-3(i)(5).

“Code” means the United States Internal Revenue Code of 1986, as currently and hereafter amended.

“Compensation Committee” means the compensation committee of the Board.

2

“Competing Business” means any business which develops, sells or markets ophthalmic pharmaceuticals.

“Disability” means a condition which renders Executive unable to engage in any substantial gainful activity as required to regularly perform Executive’sduties hereunder by reason of any medically determinable physical or mental impairment which can be expected to result in death or to last for a continuous period of not less than sixconsecutive months with or without reasonable accommodation.

“Earned Bonus” means the bonus, determined based on the actual performance of the Company for the full fiscal year in which Executive’s employment terminates, that Executive would have earned for the year in which his employment terminates had he remained employed for the entire year, prorated based on the ratio of the number of days during such year that Executive was employed to 365. Such Earned Bonus will be determined and paid to Executive no later than 2½ months after the close of the fiscal year in which the Earned Bonus was earned.

“Equity” means (i) all Stock, including restricted stock; (ii) all options and other rights to purchase Stock; (iii) all restricted stock units, performance units or phantom shares whose value is measured by the value of Stock; (iv) all stock appreciation rights whose value is measured by increases in the value of Stock; and (v) any other award under an ISP.

“Good Reason” shall mean, for purposes of Section 4(f), (i) a material diminution of Executive’s authority, duties or responsibilities; (ii) a geographic relocation of Executive’s primary business location to a location that is more than 35 miles from the present location of Executive’s primary business location; or (iii) any breach by the Company of this Agreement that is material and that is not cured within 30 days after written notice thereof to the Company from Executive.

“Good Reason” shall mean, for purposes of Section 5, that Executive resigns within 12 months after one of the following conditions has come into existence without his consent: (i) a reduction in Executive’s base salary from the amount set forth in Section 4(a) or target bonus opportunity set forth in Section 4(b); (ii) a material adverse change in Executive’s authority, responsibilities or duties; (iii) a geographical relocation of Executive’s primary business location to a location that is more than 35 miles from the present location of Executive’s primary business location; (iv) any breach by the Company of this Agreement that is material and that is not cured, or is not capable of being cured, within 30 days after written notice thereof to the Company and the Board from Executive. A condition shall not be considered “Good Reason” unless Executive gives the Company written notice of such condition within 90 days after such condition comes into existence and the Company fails to remedy such condition within 30 days after receiving Executive’s written notice.

“ISP” means the 2023 Plan and any new equity incentive plan adopted by the Company, in each caseas amended from time to time.

“Restricted Period” means the 12-month period beginning on and after Executive’s employment with the Company is terminated pursuant to the terms of this Agreement.

3

“Separation” means a “separation from service,” as defined in the regulations under Section 409A of the Code.

“Stock” means shares of the Company’s common stock.

4

SECTION 3 TITLE, POWERS AND RESPONSIBILITIES

(a) Title. Executive shall be Chief OperatingOfficer.

(b) Powers and Responsibilities.

(1) Executive in fulfilling Executive’sresponsibilities shall have such powers as are normally and customarily associated with a Chief Operating Officer in a company of similar size and operating in a similar industry, including the power to hire and fire employees and executives of the Company reporting to Executive and such other powers as are authorized by the Board.

(2) Executive, as a condition to Executive’semployment under this Agreement; represents and warrants that Executivecan assume and fulfill the responsibilities described in Section 3(b)(1) without any risk of violating any non-compete or other restrictive covenant or other agreement to which Executiveis a party.

(c) Reporting Relationship. Executive shall report to the Company’s Chief Executive Officer.

(d) Full Time Basis. Executive (1) shall undertake to perform all Executive’sresponsibilities and exercise all Executive’spowers in good faith and on a full-time basis, (2) shall not engage in any other employment, consulting or other business activity that would create a conflict of interest with the Company, (3) shall not assist any person or entity in competing with the Company or in preparing to compete with the Company and (4) shall materially comply with the Company’s policies and rules, as they may be in effect from time to time.

(e) No Conflicting Obligations.  Executive represents and warrants to the Company that Executive is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with hisobligations under this Agreement.Executive represents and warrants that Executive will not use or disclose, in connection with Executive’semployment with the Company, any trade secrets or other proprietary information or intellectual property in which Executive or any other person has any right, title or interest and that Executive’semployment with the Company will not infringe or violate the rights of any other person..

SECTION 4 COMPENSATION, BENEFITS, ETC.

(a) Annual Base Salary. Executive’s base salary shall be $450,000 per year, which amount may be reviewed and adjustedfrom time to time at the discretion of the Board or the Compensation Committee. Executive’s base salary shall be payable in accordance with the Company’s standard payroll practices and policies for executives and shall be subject to such withholdings as are required by law or as are otherwise permissible under such practices or policies.

(b) Annual Bonus. The Company shall pay an annual bonus for a fiscal year to Executive no later than 2½ months after the close of such fiscal year, in the amount, and subject to the terms and conditions of the Company’s Management Cash Incentive Program (or any predecessor or successor cash incentive plan thereto), which may be reviewed at the discretion of

5

the Board or the Compensation Committee.  Executive’s initial targetannual bonus amount shall be 40% of Executive’s annual base salary. The target annual bonus amount for the fiscal year in which Executive’s employment begins will be pro-rated based on Executive’s days of service during the fiscal year over 365.The determinations of the Board or theCompensation Committee with respect to such bonus shall be final and binding; provided, however, that Executive’s targetannual bonus amount shall not be reduced to an amount below 40% of Executive’s then-current base salary.

(c) Sign On Bonus.Within thirty (30) days of the Effective Date, the Company will pay Executive a sign-on bonus of $50,000 (the “Sign-on Bonus”). In the event of Executive’s termination by the Company for Cause or resignation without Good Reason within twelve (12) months of the Effective Date, Executive must repay to the Company the net after-tax amount of the Sign-on Bonus within sixty (60) days of such termination of employment.     

(d) Employee Benefit Plans. Executive shall be eligible to participate, on terms no less favorable to Executive than the terms for participation of any other executive of the Company at the same level within the Company as Executive, in the employee benefit plans, programs and policies maintained by the Company subject to the terms and conditions to participate in such plans, programs and policies as in effect from time to time.

(e) Equity Awards.  

(1) Stock Option. Subject to the approval of the Compensation Committee, Executive shall receive an option to purchase 225,000 shares of Stock (the “Option”) under the 2023 Plan. The exercise price of the Option shall be equal to the fair market value per share of the Stock as of the date of grant. The Option will be subject to the terms and conditions set forth in the 2023 Plan and the corresponding stock option agreement (the “Stock Option Agreement”). As will be described more fully in the Stock Option Agreement, Executive will vest in 25% of the Option shares after twelve (12) months of continuous service, and the balance will vest in equal monthly installments over the next thirty-six (36)months of continuous service.

(2) Restricted Stock Units. Subject to the approval of the Compensation Committee, Executive shall receive an award of restricted stock units for 225,000 shares of Stock (the “RSUs”) under the 2023 Plan. Such RSUs will be subject to the terms and conditions set forth in the 2023 Plan and the corresponding restricted stock unit agreement (the “RSU Agreement”). As will be more fully described in the RSU Agreement, the RSUs will vest with respect to 25% of the RSUs after twelve (12) months of continuous service, and an additional 25% will vest each year on the anniversary of the grant date over the next three (3) years of continuous service. In the event that the vesting of the RSUs is accelerated in pursuant to Section 4(f)(2) below prior to August 1, 2024, the then-vested RSUs shall be settled in cash.

(3) Performance Stock Units. Subject to the approval of theCompensation Committee, Executive shall receive an award of performance stock units for 225,000 shares of Stock (the “PSUs”) under the 2023 Plan. Such PSUs will be subject to the terms and conditions set forth in the 2023 Plan and the corresponding performance stock unit

6

agreement (the “PSU Agreement”). As will be more fully described in the PSU Agreement, the vesting of the PSUs will be conditioned on the satisfaction of either of the following performance metrics:

(A) Revenue Target.  The PSUs will vest in three equal tranches of 75,000 shares, subject to the achievement of the following milestones, as determined by the Compensation Committee following the completion of the Company’s audited financial statements for the applicable measurement year. Each tranche will vest if the (i) Company’s audited revenue for the applicable measurement year equals or exceed that annual revenue targetset forth below for the applicable year and (ii) the corporate Adjusted EBITDA (as defined in the PSU Agreement) exceeds 20% of revenuein such year (the “Revenue Target”):

Measurement Year (Number of Shares)	Annual Revenue Target
2024 (75,000)	$115,000,000
2025 (75,000)	$135,000,000
2026 (75,000)	$155,000,000

If the Revenue Target is not satisfied for a measurement year, no shares will vest for that measurement year unless the shares for such year have previously vested as a result of satisfaction of the Stock Price Target milestones (discussed below) during such measurement year or prior to such measurement year. For the avoidance of doubt, if the Revenue Target milestone is not met in one of the years, the 75,000 shares subject to the PSUs shall not be eligible to vest in a later year as a result of subsequent Revenue Target milestones being met.

(B) Stock Price Target.  Notwithstanding the Revenue Target, the PSUs will vest in three equal tranches of 75,000 shares, subject to the achievement of the following milestones. 75,000 shares will vest if the per share closing price of the Company’s Stock equals or exceeds the price in the table below for any 20 trading days within any 30-trading day periodduring the applicable measurement year (adjustments to be made for stock splits, stock dividends, reorganizations and recapitalizations) (the “Stock Price Target”): 

Measurement Year (Number of Shares)	Closing Price of Company’s Stock
2024 (75,000)	$5.10
2025 (75,000)	$6.80
2026 (75,000)	$8.50

If neither the Revenue Target nor the Stock Price Target are satisfied for a year, no PSU shares will vest for that year; however, if the Stock Price Target for a future year is achieved in a prior year then the number of vested PSUs shall be accelerated to include the number of PSUs that would have vested in such future year (e.g., if in 2024 the Stock Price Target equals or exceeds $8.50 for the applicable period,  

7

then all 225,000 PSUs shall vest in 2024, and if in 2024 the Stock Price Target does not equal or exceed $5.10, but in 2025 the Stock Price Target equals or exceeds $8.50 for the applicable period, then 150,000 of the PSUs shall vest).

In the event that the PSUs either (i) vest in accordance with the terms of the PSU Agreement or (ii) are accelerated pursuant to Section 4(f)(3) below prior to August 1, 2024, the then-vested PSUs shall be settled in cash.

The determinations of the Board or the Compensation Committee with respect to the achievement of a Revenue Target or Stock Price Target shall be final and binding.  The Board andtheCompensation Committee have discretion to modify the Revenue Targets or performance results to reflect significant transactions (such as acquisitions, divestitures, or newly-formed joint ventures) or other unusual items if such events occur following the date hereof.

(4) Other Awards.  Executive shall receive additional Equity awards at the discretion of the Board, subject to the terms and conditions set forth in the applicable ISP and any corresponding notice, agreement or certificate under the ISP.

(f) Acceleration of Vesting of Equity. The following terms shall apply to all of Executive’s Equity awards in Section 4(e), subject to Executive’s execution and non-revocation of the Release provided for in Section 5(a):

(1) The vested percentage of Executive’s Option and any other future options to purchase shares of Stock shall be determined by adding 12 months to the actual period of service that Executive has completed with the Company if Executive’s employment with the Company is terminated by the Company without Cause or Executive terminates Executive’s employment for Good Reason. (i.e., Executive’s vesting shall be accelerated by an additional 12 months).

(2) Executive shall vest in 100% of Executive’s remaining unvested Equity awardssubject to time-based vestingif (i) the Company is subject to a Change in Control and (ii) within 3 months prior to a Change in Control, on a Change in Control or in 12 months after the Change in Control, Executive’s employment with the Company is terminated by the Company (or its successor) without Cause or Executive terminates Executive’s employment for Good Reason.

(3) Executive shall vest in 100% of Executive’s unvested PSUs for the measurement year in which a Change in Control occurs (i) if the pro-rated annual revenue and Adjusted EBITDA as of the date of the Change in Control annualized would exceed the Revenue Target for the year in which the Change in Control occurs (i.e., the trajectory of the revenue for the year is on pace to exceed the Revenue Target in the year of the Change in Control as of the date of the Change in Control), as determined by the Compensation Committee and (ii) if (A) the Company is subject to a Change in Control and (B) within 3 months prior to a Change in Control, on a Change in Control or in 12 months after the Change in Control, Executive’s employment with the Company is terminated by the Company (or its successor) without Cause or Executive terminates

8

Executive’semployment for Good Reason. For the avoidance of doubt, (i) PSUs that did not vest in a prior year because the applicable Revenue Target milestone was not satisfied or the Stock Price Target milestone was not satisfied shall not be subject to any acceleration of vesting and (ii) PSUs that have not vested because the applicable measurement year has not yet occurred as of the Change in Controlshall not be subject to any acceleration of vesting under the Revenue Target milestone; provided, however, that, if the per share closing price of the Company’s Stock equals or exceeds the Stock Price Target, disregarding the trading day requirement, for a future year upon the Change in Control, then the number of vested PSUs shall be accelerated to include the number of PSUs that would have vested in such future year.

(4) If the Company is a party to a merger or consolidation, all Executive’s outstanding Equity shall vest in full unless the agreement evidencing the merger or consolidation provides for one or more of the following:

(C) The continuation of such outstanding Equity by the Company (if the Company is the surviving corporation).

(D) The assumption of such outstanding Equity by the surviving corporation or its parent.

(E) The substitution by the surviving corporation or its parent of new Equity for such outstanding Equity.

(F) Full exercisability of outstanding Equity and full vesting of the Stock subject to such Equity, followed by the cancellation of such Equity. The full exercisability of such Equity and full vesting of such Stock, as applicable, may be contingent on the closing of such merger or consolidation.

(G) The cancellation of outstanding Equity and a payment to Executive equal to the excess of (i) the fair market value of the Stock subject to such Equity (whether or not such Equity is then exercisable or vested, as applicable) as of the closing date of such merger or consolidation over (ii) the exercise price. Such payment shall be made in the form of cash, cash equivalents or securities of the surviving corporation or its parent with a fair market value equal to the required amount. Such payment may be made in installments and may be deferred until the date or dates when such Equity would have become exercisable or such Stock would have vested. Such payment may be subject to vesting based on Executive’s continuing service, provided that the vesting schedule shall not be less favorable to Executive than the schedule under which such Equity would have become exercisable or such Stock would have vested. This provision is mandatory in the event that the Company is acquired by a private company for cash.

(5) Executive shall vest in 100% of the remaining unvested Equity in the event of Disability where a Separation occurs or death.

(g) Rights to Time Off Work. Executive shall be eligible for paid time off in accordance with the Company paid time off policies, as in effect from time to time.  

9

(h) Expense Reimbursements. Executive shall have the right to expense reimbursements in accordance with the Company’s standard policy on expense reimbursements, as in effect from time to time. Any reimbursement shall (a) be paid promptly but not later than the last day of the calendar year following the year in which the expense was incurred, (b) not be affected by any other expenses that are eligible for reimbursement in any calendar year and (c) not be subject to liquidation or exchange for another benefit.

(i) Indemnification. The Company shall, to the maximum extent permitted by applicable law and the Company’s governing documents, indemnify Executive and hold Executive harmless from and against any claim, loss or cause of action arising from or out of Executive’s performance as an officer, director, manager or employee of the Company or in any other capacity in which Executive serves at the request of the Board. If any claim is asserted hereunder against Executive, the Company shall pay Executive’s legal expenses (or cause such expenses to be paid) on a quarterly basis, provided that Executive shall reimburse the Company, in a timely manner, for such amounts if Executive shall be found by a final, non-appealable order of a court of competent jurisdiction not to be entitled to indemnification. The indemnification obligations of the Company in this paragraph shall survive any termination of this Agreement and shall be supplemental to any other rights to indemnification from the Company to which Executive is entitled.

(j) Directors and Officers Liability Insurance. The Company shall maintain directors’ and officers’ liability insurance coverage covering Executive in amounts customary for similarly situated companies in the pharmaceutical industry and with insurers reasonably acceptable to Executive. All policies for such coverage shall provide for insurance on an “occurrence” basis, or if on a “claims-made” basis, with sufficient coverage for claims made after the date on which Executive’s employment with the Company terminates.

(k) At-Will Employment. Executive’s employment with the Company shall be “at will,” meaning that either Executive or the Company shall be entitled to terminate Executive’s employment at any time and for any or no reason, with or without Cause or Good Reason. Any contrary representations that may have been made to Executive shall be superseded by this Agreement. This Agreement shall constitute the full and complete agreement between Executive and the Company on the “at will” nature of Executive’s employment, which may only be changed in an express written agreement signed by Executive and a duly authorized officer of the Company(other than Executive).

SECTION 5 TERMINATION OF EMPLOYMENT

(a) General.  If the Board terminates Executive’s employment without Cause or Executive resigns for Good Reason and a Separation occurs, then Executive will be entitled to the benefits described inSection 4(f) or this Section 5. However, Executive will not be entitled to any of the benefits described in Section 4(f) or this Section 5 unless Executive has (i) returned all Company property in Executive’s possession and (ii) executed a general release of all claims that Executive may have against the Company or persons affiliated with the Company in a form prescribed by the Company (the “Release”), with applicable carve outs for rights to indemnification, enforcement of this Release and to vested Equity. Executive must execute and return the Release on or before the date specified by the Company in the Release (the “Release

10

Deadline”). The Release Deadline will in no event be later than fifty (50) days after Executive’s Separation. If Executive fails to return the executed Release on or before the Release Deadline, or if Executive revokes the Release within seven (7) days afterreturn of the executed Release, then Executive will not be entitled to the benefits described in this Section 5.

(b) Termination by Board without Cause or by Executive for Good Reason Not in Connection with Change in Control. If the Board terminates Executive’s employment without Cause or Executive resigns for Good Reason and a Separation occurs either more than three months prior to a Change in Control or more than 18 months after a Change in Control, the Company shall pay Executive his earned but unpaid base salary plus 100% of the sum of (i) Executive’s current total annual base salary plus (ii) Executive’s target annual bonus for the then current year (subject to such withholdings as required by law) payable in twelve equal monthly installments.In addition, Executive shall be paid, no later than 2½ months following the close of the fiscal year of termination, Executive’sEarned Bonus for the fiscal year in which the Separation occurs. The salary continuation payments and shall commence within 60 days after Executive’s Separation and, once they commence, shall include any unpaid amounts accrued from the date of Separation. However, if such 60-day period spans two calendar years, then the payments will in any event begin in the second calendar year. In addition, the Company shall make any continuation coverage premium payments (for Executive and Executive’s dependents) for continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”)for the one-year period following the Separation or, if earlier, until Executive is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer. Notwithstanding the foregoing, if the Company, in its sole discretion, determines that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company to incur additional expense as a result of noncompliance with applicable law (including Section 2716 of the Public Health Service Act), the Company instead shall provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the group health coverage in effect on the date of the Separation (which amount shall be based on the premium for the first month of COBRA coverage), which payments (i) shall be made regardless of whether Executive elects COBRA continuation coverage, (ii) shall commence on the later of (A) the first day of the month following the month in which Executive experiences a Separation and (B) the effective date of the Company’s determination of violation of applicable law, and (iii) shall end on the earliest of (x) the effective date on which Executive becomes covered by a medical, dental or vision insurance plan of a subsequent employer, and (y) the last day of the period one year after Separation. Executive shall have no right to an additional gross-up payment to account for the fact that such COBRA premium amounts are paid on an after-tax basis.

(c) Termination by Board without Cause or by Executive for Good Reason in Connection with Change in Control. If the Board terminates Executive’s employment without Cause or Executive resigns for Good Reason and a Separation occurs either within three months prior to a Change in Control or within 18 months after a Change in Control, the Company shall pay Executive his earned but unpaid base salary plus the sum of (i) 150% of Executive’scurrent total annual base salary plus (ii) 100% ofExecutive’starget annual bonus for the then current year(subject to such withholdings as required by law),payable in eighteen equal monthly installments (the “Severance Payments”). In addition, Executive shall be paid, no later than 2½ months following the close of the fiscal year of termination, Executive’sEarned Bonus for the fiscal year

11

in which the Separation occurs. The Severance Payments shall commence within 60 days after Executive’s Separation. However, if such 60-day period spans two calendar years, then the payments will in any event begin in the second calendar year. In addition, the Company shall make any continuation coverage premium payments (for Executive and Executive’s dependents) for continued health insurance coverage under the COBRA for the 18-month period following the Separation or, if earlier, until Executive is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer. Notwithstanding the foregoing, if the Company, in its sole discretion, determines that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company to incur additional expense as a result of noncompliance with applicable law (including Section 2716 of the Public Health Service Act), the Company instead shall provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the group health coverage in effect on the date of the Separation (which amount shall be based on the premium for the first month of COBRA coverage), which payments (i) shall be made regardless of whether Executive elects COBRA continuation coverage, (ii) shall commence on the later of (A) the first day of the month following the month in which Executive experiences a Separation and (B) the effective date of the Company’s determination of violation of applicable law, and (iii) shall end on the earliest of (x) the effective date on which Executive becomes covered by a medical, dental or vision insurance plan of a subsequent employer, and (y) the last day of the period 18 months after Separation. Executive shall have no right to an additional gross-up payment to account for the fact that such COBRA premium amounts are paid on an after-tax basis.

(d) Termination by the Board for Cause or by Executive without Good Reason. If the Board terminates Executive’s employment for Cause or Executive resigns without Good Reason, the Company’s only obligation to Executive under this Agreement shall be to pay Executive his earned but unpaid base salary, if any, up to the date Executive’s employment terminates, and Executive shall have no right to any Earned Bonus or any unpaid bonus payment whatsoever. The Company shall only be obligated to reimburse any unreimbursed business expenses and to make such payments and provide such benefits under any employee benefit plan, program or policy in which Executive was a participant as are explicitly required to be paid to Executive by the terms of any such benefit plan, program or policy following the date on which Executive’s employment terminates.

(e) Termination for Disability. The Board shall have the right to terminate Executive’s employment on or after the date Executive has a Disability, and such a termination shall not be treated as a termination without Cause under this Agreement. If Executive’s employment is terminated on account of a Disability and a Separation occurs, the Company shall:

(1) pay Executive Executive’sbase salary through the end of the month in which a Separation occurs as soon as practicable after the Separation,

(2) pay Executive Executive’sEarned Bonus for the fiscal year in which such Separation occurs; provided that the Earned Bonus shall in no event be paid later than 2½ months after the close of such fiscal year,

12

(3) pay or cause the payment of benefits to which Executive is entitled under the terms of the disability plan(s) of the Company covering Executive at the time of such Disability,

(4) make such payments and provide such benefits as otherwise called for under the terms of the ISP and each other employee benefit plan, program and policy in which Executive was a participant; provided that no payments made under Section 5(e)(l),  Section 5(e)(2) or Section 5(e)(3) shall be taken into account in computing any payments or benefits described in this Section 5(e)(4), and

(5) make any COBRA continuation coverage premium payments (for Executive and for Executive’s dependents), for the 18-month period following the termination of Executive’s employment or, if earlier, until Executive is eligible to be covered under another substantially equivalent medical insurance plan by a subsequent employer. Notwithstanding the foregoing, if the Company, inits sole discretion, determines that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company to incur additional expense as a result of noncompliance with applicable law (including Section 2716 of the Public Health Service Act), the Company instead shall provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the group health coverage in effect on the date of the Separation (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage, shall commence on the later of (i) the first day of the month following the month in which Executive experiences a Separation and (ii) the effective date of the Company’s determination of violation of applicable law, and shall end on the earliest of (x) the effective date on which Executive becomes covered by a medical, dental or vision insurance plan of a subsequent employer, and (y) the last day of the period 18 months after Separation. Executive shall have no right to an additional gross-up payment to account for the fact that such COBRA premium amounts are paid on an after-tax basis.

(f) Death. If Executive’s employment terminates because of his death, the Company shall:

(1) pay to Executive’s estate Executive’s base salary through the end of the month of his death as soon as practicable after his death,

(2) pay to Executive’s estate Executive’s Earned Bonus, when actually determined, for the year in which Executive’s death occurs,

(3) make such payments and provide such benefits as otherwise called for under the terms of the ISP and each other employee benefit plan, program and policy in which Executive was a participant; provided that no payments made under Section 5(f)(1) or Section 5(f)(2) shall be taken into account in computing any payments or benefits described in this Section 5(f)(3), and

13

(4) make any COBRA continuation coverage premium payments for Executive’s dependents for the one-year period following Executive’s death or, if earlier, until such dependents are eligible to be covered under another substantially equivalent medical insurance plan. Notwithstanding the foregoing, if the Company, in its sole discretion, determines that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company to incur additional expense as a result of noncompliance with applicable law (including Section 2716 of the Public Health Service Act), the Company instead shall provide a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive’s dependents would be required to pay to continue the group health coverage in effect on the date of Executive’s death (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive’s dependents elect COBRA continuation coverage, shall commence on the later of (i) the first day of the month following the month in which Executive dies and (ii) the effective date of the Company’s determination of violation of applicable law, and shall end on the earliest of (x) the effective date on which Executive’s dependents become covered under another substantially equivalent medical insurance plan, and (y) the last day of the period one year after Executive’s death. Executive’s dependents shall have no right to an additional gross-up payment to account for the fact that such COBRA premium amounts are paid on an after-tax basis.

SECTION 6 COVENANTS BY EXECUTIVE

(a) Company Property. Upon the termination of Executive’s employment for any reason, or upon any earlier Company request, Executive shall promptly return all Company Property that had been entrusted or made available to Executive by the Company, where the term “Property”means all Company-related records, files, memoranda, reports, price lists, customer lists, drawings, plans, sketches, keys, codes, computer hardware and software and other property of any kind or description prepared, used or possessed by Executive during Executive’s employment by the Company (and any duplicates of any such Property), together with any and all information, ideas, concepts, discoveries, and inventions and the like conceived, made, developed or acquired at any time by Executive individually or with others during Executive’s employment that relate to the Company or its products or services.

(b) Trade Secrets. Executive agrees that Executive shall hold in a fiduciary capacity in perpetuity for the sole benefit of the Company and its affiliates and shall not directly or indirectly use or disclose any Trade Secret that Executive may have acquired (whether or not developed or compiled by Executive and whether or not Executive is authorized to have access to such information) during the term of Executive’s employment by the Company or any of its predecessors for so long as such information remains a Trade Secret, where the term “Trade Secret”means information, including technical or non-technical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing or a process that (1) derives economic value, actual or potential, from not being generally known to, and not being generally readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and (2) is the subject of reasonable efforts by the Company and any of its affiliates to maintain its secrecy. This Section 6(b)is intended to provide rights to the Company and its

14

affiliates which are in addition to, not in lieu of, those rights the Company and its affiliates have under the common law or applicable statutes for the protection of trade secrets.

(c) Confidential Information. Executive while employed by the Company or its affiliates and for the three-year period thereafter shall hold in a fiduciary capacity for the sole benefit of the Company and its affiliates, and shall not directly or indirectly use or disclose, any Confidential Information that Executive may have acquired (whether or not developed or compiled by Executive and whether or not Executive is authorized to have access to such information) during the term of and in the course of or as a result of Executive’s employment by the Company or its predecessors without the prior written consent of the Board unless and except tothe extent that such disclosure is (i) made in the ordinary course of Executive’s performance of his duties under this Agreement or (ii) required by any subpoena or other legal process (in which event Executive will give the Company prompt notice of such subpoena or other legal process in order topermit the Company toseek appropriate protective orders). For the purposes of this Agreement, the term “Confidential Information” means any secret, confidential, or proprietary information possessed by the Company or any of its affiliates, including trade secrets, customer or supplier lists, details of client or consultant contracts, current and anticipated customer requirements, pricing policies, price lists, market studies, business plans, operational methods, marketing plans or strategies, product flaws or development techniques, computer software programs (including object code and source code), data and documentation data, base technologies, systems, structures and architectures, inventions and ideas, past current and planned research and development, compilations, devices, methods, techniques, processes, financial information and data, business acquisition plans, and new personnel acquisition plans (not otherwise included as a Trade Secret under this Agreement) that has not become generally available to the public, and the term “Confidential Information” may include future business plans, licensing strategies, advertising campaigns, information regarding customers or suppliers, executives and independent contractors and the terms and conditions of this Agreement. Notwithstanding the provisions of this Section 6(c) to the contrary, Executive shall be permitted to furnish this Agreement to a subsequent employer or prospective employer.

(d) Non-solicitation of Customers or Employees.

(1) Executive (i) while employed by the Company or any of its affiliates shall not, on Executive’s own behalf or on behalf of any person, firm, partnership, association, corporation or business organization, entity or enterprise (other than the Company or one of its affiliates), solicit business for a Competing Business from customers or suppliers of the Company or any of its affiliates and (ii) during the Restricted Period shall not, on Executive’s own behalf or on behalf of any person, firm, partnership, association, corporation or business organization, entity or enterprise, solicit business for a Competing Business from customers or suppliers of the Company or any of its affiliates with whom Executive, in the case of both clauses (i) and (ii) above, had or made material business contact with in the course of Executive’s employment by the Company within the 24-month period immediately preceding the beginning of the Restricted Period.

(2) Executive (i) while employed by the Company or any of its affiliates shall not, either directly or indirectly, call on, solicit or attempt to induce any other officer, employee or independent contractor of the Company or any of its affiliates to terminate his

15

or her employment with such business and shall not assist any other person or entity in such a solicitation (regardless of whether any such officer, employee or independent contractor would commit a breach of contract by terminating his or her employment), and (ii) during the Restricted Period, shall not, either directly or indirectly, call on, solicit or attempt to induce any other officer, employee or independent contractor of such business with whom Executive had contact, knowledge of, or association in the course of Executive’s employment with the Company or any of its predecessors or affiliates, as the case may be, during the 12-month period immediately preceding the beginning of the Restricted Period, to terminate his or her employment with the Company or any of its affiliates and shall not assist any other person or entity in such a solicitation (regardless of whether any such officer, employee or independent contractor would commit a breach of contract by terminating his or her employment). Notwithstanding the foregoing, nothing shall prohibit any person from contacting Executive about employment or other engagement during the Restricted Period, provided that Executive does not solicit the contact.

(e) Non-competition Obligation. Without the prior written consent of the Company, Executive, while employed by the Company or any of its affiliates and thereafter until the end of the Restricted Period, will not engage in any of the activities described in Section 3(b)(l) hereof within the geographical area in which the Company or any of its affiliates is actively engaged in developing, marketing and selling ophthalmic pharmaceuticals, for himself or on behalf of any other person, partnership, corporation or other business entity that is a Competing Business for the purpose of competing with the Company. Notwithstanding the preceding sentence, Executive will not be prohibited from owning less than 5% percent of any publicly traded corporation, whether or not such corporation is in a Competing Business.

(f) Reasonable and Continuing Obligations. Executive agrees that Executive’s obligations under this Section 6 are obligations which will continue beyond the date Executive’s employment terminates and that such obligations are reasonable, fair and equitable in scope, terms and duration, are necessary to protect the Company’s legitimate business interests, and are a material inducement to the Company to enter into this Agreement.

(g) Remedy for Breach. Executive agrees that the remedies at law of the Company for any actual or threatened breach by Executive of the covenants in this Section 6 would be inadequate and that the Company shall be entitled to specific performance of the covenants in this Section 6, including entry of a temporary restraining order in state or federal court, preliminary and permanent injunctive relief against activities in violation of this Section 6, or both, or other appropriate judicial remedy, writ or order, in addition to any damages and legal expenses which the Company may be legally entitled to recover. The Company agrees, however, to give Executive and, if known, Executive’s attorney reasonable advance notice of any legal proceeding, including any application for a temporary restraining order, relating to an attempt to enforce the covenants in this Section 6 against Executive. Executive acknowledges and agrees that the covenants in this Section 6 shall be construed as agreements independent of any other provision of this Agreement or any other agreement between the Company and Executive, and that the existence of any claim or cause of action by Executive against the Company, whether predicated upon this Agreement or any other agreement, shall not constitute a defense to the enforcement by the Company of such covenants.

16

(h) Termination of Restrictive Covenants. In addition to any other right or remedy available to Executive, Executive shall no longer be bound by any of the restrictions set forth in this Section 6 if the Company fails to pay or to provide Executive when due the amounts and benefits due hereunder or under any agreement ancillary hereto, and Executive’s pursuit of such remedy shall not relieve the Company from its obligations to pay and to provide such amounts and benefits to Executive.

(i) Ownership of Inventions, Discoveries, Improvements, Etc.

(1) Executive shall promptly disclose and describe to the Company all inventions, improvements, discoveries and technical developments, whether or not patentable, made or conceived by Executive, either alone or with others, during such time as Executive is employed with the Company, and within one year after the date upon such employment terminates, that (i) are based in whole or in part upon Confidential Information or (ii) during such time as Executive is employed with the Company are along the lines of, useful in or related to the business of the Company or (iii) result from or are suggested by any work done by Executive for or on behalf of the Company (“Inventions”). Executive hereby assigns and agrees to assign to the Company Executive’s entire right, title and interest in and to such Inventions (the “Assigned Inventions”), and agrees to cooperate with the Company both during and after such time as Executive is employed with the Company in the procurement and maintenance, at the Company’s expense and at its direction, of patents and copyright registrations and/or other protection of the Company’s rights in such Inventions. Executive shall keep and maintain adequate and current written records of all such Inventions, which shall be and remain the property of the Company.

(2) If a patent application, trademark registration or copyright registration is filed by Executive or on Executive’s behalf, or a copyright notice indicating Executive’s authorship is used by Executive or on Executive’s behalf, within one year after the date on which Executive’s employment with the Company terminates, that describes or identifies any Invention within the scope of Executive’s work for the Company or that otherwise related to a portion of the Company’s business (or any division thereof) of which Executive had knowledge such time as Executive was employed with the Company, it is to be conclusively presumed that the Invention was conceived by Executive during the such time as Executive was employed with the Company. Executive agrees to notify the Company promptly of any such application or registration and to assign to the Company Executive’s entire right, title and interest in such Invention and in such application or registration.

(3) If (i) Executive uses or discloses any of Executive’s own or any third party’s confidential information or intellectual property (collectively, “Restricted Materials”) when acting within the scope of Executive’s employment (or otherwise on behalf of the Company) or (ii) any Assigned Invention cannot be fully made, used, reproduced or otherwise exploited without using or violating any Restricted Materials, Executive hereby grants and agrees to grant to the Company a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such Restricted Materials and intellectual property rights therein. Executive will not use or disclose any Restricted Materials for which Executive is not fully authorized to grant the foregoing license.

17

(4) To the extent allowed by applicable law, the terms of this Section 6(i) include all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as moral rights, artist’s rights, droit moral or the like (collectively, “Moral Rights”). To the extent Executive retains any such Moral Rights under applicable law, Executive hereby ratifies and consents to any action that may be taken by or authorized by the Company with respect to such Moral Rights and agrees not to assert any Moral Rights with respect thereto. Executive will confirm any such ratification, consent or agreement from time to time as requested by the Company.

SECTION 7 MISCELLANEOUS

(a) Notices. Notices and all other communications shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by United States registered or certified mail. Notices to the Company shall be sent to:

Alimera Sciences, Inc.

Attention: Chief Financial Officer

6310 Town Square, Suite 400

Alpharetta, Georgia 30005

Notices and communications to Executive shall be sent to the address Executive most recently provided to the Company.

(b) No Waiver. Except for the notice described in Section 7(a), no failure by either the Company or Executive at any time to give notice of any breach by the other of, or to require compliance with, any condition or provision of this Agreement shall be deemed a waiver of any provisions or conditions of this Agreement.

(c) Tax Matters.

(1) All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law.  The Company intends that all payments and benefits provided under this Agreement or otherwise are exempt from, or comply with, with the requirements of Section 409A of the Code (“Section 409A”)so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted in accordance with such intent.Specifically, to the extent necessary to avoid the imposition of tax on Executive under Section 409A, payments payable upon a termination or separation shall be suspended until the first business day following(i) six (6) months from effective date of termination or separation or (ii) the date of Executive’s death, if, immediately prior to Executive’s termination or separation, Executive is a “specified employee” (within the meaning of Code Section 409A(a)(2)(B)(i)) and Section 409A would require the delay of such payment to avoid any penalties thereunderand any installments that otherwise would have been paid or provided prior to such date will be paid or provided in a lump sum when the severance payments or benefits commence. Each payment hereunder shall be deemed a separate payment for purposes of Section 409A. The parties intend that no payment pursuant to this Agreement shall give rise to any adverse tax consequences to either party

18

pursuant to Section 409A; provided, however, that Executive acknowledges that the Company does not guarantee any particular tax treatment and that Executive is solely responsible for any taxes Executive incurs pursuant to Section 409A, if any, as a result of this Agreement.The Company shall not have a duty to design its compensation policies in a manner that minimizes Executive’s tax liabilities, and Executive agrees not to make any claim against the Company or the Board related to tax liabilities arising from Executive’s compensation.

(2) If any payment or benefit that Executive would receive in connection with an acquisition of ownership or effective control of the Company or ownership of a substantial portion of the Company’s assets (within the meaning of section 280G of the Code and the regulations thereunder)(the “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, any reduction shall be applied first, on a pro rata basis, to amounts that constitute deferred compensation within the meaning of Section 409A of the Code, and, in the event that the reductions pursuant to this Section 7(c)(2) exceed payments that are subject to Section 409A of the Code, the remaining reductions shall be applied, on a pro rata basis, to any other remaining payments,  first with respect to amounts payable in cash before being made in respect to any payments to be provided in the form of benefits or Equity award acceleration, and in the form of benefits before being made with respect to Equity award acceleration. The Company’s determinations hereunder shall be final, binding and conclusive on all interested parties.

(3) Delaware Law.  This Agreement shall be governed by the laws of the state of Delaware without regard to its provisions regarding choice of law or conflicts of law.

(4) Arbitration.  Any controversy or claim arising out of this Agreement and any and all claims relating to Executive’s employment with the Company will be settled by final and binding arbitration.  The arbitration will take place in the State of Georgia.  The arbitration will be administered by the American Arbitration Association under its National Rules for the Resolution of Employment Disputes. Any award or finding will be confidential.  Executive and the Company agree to provide one another with reasonable access to documents and witnesses in connection with the resolution of the dispute.  Executive and the Company will share the costs of arbitration equally up to, for Executive, the filing fee to bring a civil action in the state courts of Georgia.  Each party will be responsible for its own attorneys’ fees, and the arbitrator may not award attorneys’ fees unless a statute or contract at issue specifically authorizes such an award.  This Section 7(c)(4) does not apply to claims for workers’ compensation benefits or unemployment

19

insurance benefits.  This Section 7(c)(4) also does not apply to claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held or sought by either Executive or the Company (whether or not arising under Section 6).

(5) Assignment. This Agreement shall be binding upon and inure to the benefit of the Company and any successor in interest to the Company. The Company may assign this Agreement to any affiliate or successor that acquires all or substantially all of the assets and business of the Company or a majority of the voting interests of the Company, and no such assignment shall be treated as a termination of Executive’s employment under this Agreement. Executive’s rights and obligations under this Agreement are personal and shall not be assigned or transferred.

(6) Other Agreements. This Agreement replaces and merges any and all previous agreements and understandings regarding all the terms and conditions of Executive’s employment relationship with the Company, including the Prior Agreement, and this Agreement constitutes the entire agreement between the Company and Executive with respect to such terms and conditions.

(7) Amendment. No amendment to this Agreement shall be effective unless it is in writing and signed by an authorized officer of the Company(other than Executive) and Executive.

(8) Invalidity. If any part of this Agreement becomes or isdeemedinvalid or otherwise unenforceable, the remaining part shall be unaffected and shall continue in full force and effect, and the invalid or otherwise unenforceable part shall be deemed not to be part of this Agreement.

(9) Interpretation. The recitals to this Agreement shall be taken into account in the construction or interpretation of this Agreement. The words “include,” “includes” and “including” are deemed to be followed by the phrase “without limitation.” The captions or headings of the Sections and other subdivisions of this Agreement are inserted only as a matter of convenience or reference and have no effect on the meaning of the provisions of those Sections or subdivisions. If the provisions of this Agreement require judicial interpretation, the parties agree that the judicial body interpreting or construing the Agreement may not apply the assumption that the terms must be more strictly construed against one party by reason of the rule of construction that an instrument is to be construed more strictly against the party that itself or through its agents prepared the instrument.

(10) Survival. The respective indemnities, representations, warranties, agreements and covenants of the Company and Executive contained in this Agreement shall survive the termination of this Agreement and shall remain in full force and effect.

(11) Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

20

[The remainder of this page intentionally left blank]

21

IN WITNESS WHEREOF, the Company and Executive have executed this Agreement in multiple originals as of the Effective Date.

ALIMERA SCIENCES, INC. EXECUTIVE

By:	/s/ Richard S. Eiswirth	By:	/s/ Jason Werner
	Richard S. Eiswirth,  President and Chief Executive Officer		Jason Werner
Date:	October 2, 2023	Date:	October 2, 2023

Signature Page to Employment Agreement between
Jason Werner and Alimera Sciences, Inc.

EX-99.1

Exhibit 99.1

Alimera Sciences Appoints Jason Werneras Chief Operating Officer

Dr. Philip Ashman Appointed asPresident of International Operations

ATLANTA, October 3,  2023--Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer,  today announced the appointment ofJason Werner, Chief Operating Officer (“COO”), effective October 2, 2023.In conjunction with this appointment, Dr. Philip Ashman,previously Alimera’sChief Operating Officer andSenior Vice President, Commercial Operations Europe,was appointed President of International Operations.

“Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we are grateful to him for transitioning to this extremely important operational role,” said Rick Eiswirth, President and CEO of Alimera. “His extensive background in ophthalmics, along with his experience in previous roles in commercial development and corporate strategy, will be ideal in overseeing our manufacturing and regulatory efforts globally as we accelerate our growth trajectory.”

Mr. Werner hasserved as adirector of Alimera since Q2 2023. Prior to joining Alimera’s management team he has served as the Chief Executive Officer and Board Member of SightStream Biotherapeutics Inc, a biotechnology company focused on developing regenerative medicines in ophthalmics. Mr. Werner also currently serves on the board of directors of InflammX Therapeutics Inc, a privately held developer of novel treatments of the Inflammasome (NLRP3) Pathway based in San Diego, California.  Mr. Werner previously co-founded and served as Chief Operating Officer of Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals Ltd. He has held a variety of commercial development roles and corporate strategy positions at companies such as Sun Pharma, Nicox SA and Inspire Pharmaceuticals, all within the field of ophthalmics. Mr. Werner received his B.S. in business administration from the University of New Hampshire.

“Since joining Alimera’s Board of Directors earlier this year, I have had the privilege of working closely with this great team as we integrated the YUTIQbrand and completed a successful recapitalization of the balance sheet,” said Mr. Werner. “I strongly believe the recent acquisition of the YUTIQ brand along with the global growth of ILUVIEN will be transformational for Alimera and I am excited to be in a position to meaningfully contribute to the company’s continued growth in the retina space.”

Mr. Eiswirth added,“I look forward to Alimera’s benefitting from Philip’s established expertise in commercial operations in his newly expanded role as we look to continue growing utilization of ILUVIEN across all of our international markets.”

About Alimera Sciences, Inc.

Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For investor inquiries:                                         For media inquiries:

Scott Gordon                                                          Jules Abraham

for Alimera Sciences                                              for Alimera Sciences
scottg@coreir.comjulesa@coreir.com

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, Alimera’s expectations with respect to its business strategy, future operations, projected growth, and anticipated impact of the YUTIQ acquisition. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplates,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based on current expectations and involve inherent risks and uncertainties (some of which are beyond Alimera’s control), including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s most recently filed Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q, and any of Alimera’s subsequent filings with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely on the forward-looking statements Alimera makes or that are made on its behalf as predictions of future events. These forward-looking statements speak only as of the date of this press release. Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as aresult of new information, future events or otherwise, except as may be required under applicable securities laws.

XML

Document and Entity Information	Oct. 02, 2023
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Oct. 02, 2023
Entity Registrant Name	ALIMERA SCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-34703
Entity Tax Identification Number	20-0028718
Entity Address, Address Line One	6310 Town Square
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	990-5740
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	ALIM
Security Exchange Name	NASDAQ
Emerging Growth Company	false
Entity Central Index Key	0001267602
Amendment Flag	false